✦ LIBER ✦

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

✍ Scribed by Shami, P J; Deininger, M

Book ID: 125809595
Publisher: Nature Publishing Group
Year: 2011
Tongue: English
Weight: 421 KB
Volume: 26
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2011.217

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Critical Review of Trials of First-Lin

A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

✍ Jabbour, Elias; Lipton, Jeffrey H. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 355 KB

Outcome After Failure of Second Generati

Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia

✍ Eghtedar, Alireza; Kantarjian, Hagop; Jabbour, Elias; O'Brien, Susan; Burton, El 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 439 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

PCN92 Cost-Effectiveness of Nilotinib Ve

PCN92 Cost-Effectiveness of Nilotinib Versus Imatinib as First-Line Treatment for Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Russian Federation

✍ R. Yagudina; A. Kulikov; I. Komarov 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN57 Cost Effectiveness of Nilotinib Ve

PCN57 Cost Effectiveness of Nilotinib Versus Imatinib as First Line Treatment for Newly Diagnosed Hong Kong (HK) Patients With Chronic Phase, Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Hong Kong

✍ Tse, V.; Liu, H.; Botteman, M.; Mcghee, S.; Lee, V.W.; Lee, K.K. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB